Crohn’s Disease in India: A Multicenter Study from a Country Where Tuberculosis Is Endemic
- 4 September 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in Digestive Diseases and Sciences
- Vol. 54 (5), 1099-1107
- https://doi.org/10.1007/s10620-008-0469-6
Abstract
Although Crohn’s disease is thought to be rare and intestinal tuberculosis common in India, Crohn’s disease is being reported more often. However, there is a lack of systematic study on Crohn’s disease from India. In this analysis of data from three inflammatory bowel disease clinics (two in northern India and one in eastern India), criteria for Crohn’s disease were applied retrospectively: (1) World Health Organization (WHO) criteria; or (2) compatible histology (European Crohn’s and Colitis Organization) or failure of response to 4–8 weeks of anti-tuberculosis therapy (Asia-Pacific guidelines); or (3) compatible macroscopic, radiologic, colonoscopic features (European Crohn’s and Colitis Organization). Others were classified as probable Crohn’s disease. The Montreal classification was used for disease phenotype. Age at onset and duration of symptoms (182 patients, 117 male) were 34.5 (±13.6; 7–73) years and 3.0 (±5.8; 0.1–36) years, respectively. Diarrhea (68%), abdominal pain (62%), and weight loss (57%) were common. The common intestinal complications were occult (27%) and overt (40%) gastrointestinal bleeding and obstruction (28%). There were 141 (78%) and 41 (22%) with definite and probable Crohn’s disease respectively. Of 147 (81%) available histopathology specimens (endoscopic biopsy in 110; 75%), 31 (21%) had granuloma. Seventy-one out of 166 (43%) had received anti-tuberculosis therapy in the past. Results from the Montreal classification were as follows: age at onset, A1:A2:A3 6%:64%:30%; location of disease, L1:L2:L3:L4 32%:41%:23%:4%, and disease behavior, B1:B2:B3 51%:24%:25%. Twenty-six (15%) and 31 (17%) patients had upper gastrointestinal and perianal modifiers. The drugs used were: aminosalicylates (128, 70%), steroids (76, 42%), azathioprine (53, 29%), methotrexate (4, 2%), and salazopyrine (14, 8%). Sixty-six (36%) patients underwent surgical treatment. We concluded that the phenotype of Crohn’s disease in India is very similar to that described in other regions of Asia and the West, except for a delay in diagnosis and a more complicated disease at diagnosis.This publication has 40 references indexed in Scilit:
- Intestinal permeability and its association with the patient and disease characteristics in Crohn’s diseaseWorld Journal of Gastroenterology, 2008
- Mortality by Medication Use Among Patients With Inflammatory Bowel Disease, 1996–2003Gastroenterology, 2007
- Review article: the diagnosis and management of Crohn’s disease in populations with high‐risk rates for tuberculosisAlimentary Pharmacology & Therapeutics, 2007
- Anti-Saccharomyces cerevisiae antibody is not useful to differentiate between Crohn′s disease and intestinal tuberculosis in IndiaJournal of Postgraduate Medicine, 2007
- Management consensus of inflammatory bowel disease for the Asia–Pacific regionJournal of Gastroenterology and Hepatology, 2006
- The Montreal classification of inflammatory bowel disease: controversies, consensus, and implicationsGut, 2006
- Rising incidence and prevalence of Crohn’s disease in Asia: Is it apparent or real?Journal of Gastroenterology and Hepatology, 2006
- Retrospective analysis of 515 cases of Crohn’s disease hospitalization in China: Nationwide study from 1990 to 2003Journal of Gastroenterology and Hepatology, 2006
- Antibacterial and antimycobacterial treatment for inflammatory bowel diseaseJournal of Gastroenterology and Hepatology, 2005
- Frequency and significance of granulomas in a cohort of incident cases of Crohn's diseaseGut, 2005